Preparation method and application of self-assembled polypeptide with targeting effect on CD36 protein
Through the design of self-assembled polypeptides, the R1, R2, and R3 units connected by amide bonds are used to combine amino acids fixed by Wang resin to prepare polypeptides with targeted CD36 protein, which solves the shortcomings of targeted CD36 protein and achieves the CD36 protein The specific blockade and tumor treatment effect demonstrate unique advantages in tumor treatment.
Patent Information
- Application Number
- CN202410459304.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-17
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-04-17
AI Technical Summary
In the prior art, there are few targeted therapeutic drugs for CD36 protein, and it is difficult to effectively regulate the fatty acid metabolism of Treg cells, resulting in immunosuppression and affecting the tumor treatment effect.
A self-assembled polypeptide composed of R1 hydrophobic unit, R2 self-assembly unit and R3 specific targeting unit is used to prepare a polypeptide with targeting CD36 protein by amide bonding, combining the amino acids fixed by Wang resin and Fmoc or Boc-protected amino acids. Block CD36 receptor function by non-covalent bonds or intermolecular forces.
The specific binding and functional blockade of CD36 protein was achieved, which significantly enhanced the anti-tumor activity of immune cells, had potential application prospects for diagnosis and treatment of tumors, and was low in cost and high specificity.
Smart Images

Figure CN119039455A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedical technology, and in particular relates to a preparation method and application of a self-assembling polypeptide having a targeting effect on CD36 protein. Background Art
[0002] Malignant tumors are major diseases that seriously endanger the lives and health of the Chinese people. In the past decade, the average annual increase in incidence has been as high as 3.9%, and the average annual increase in mortality has reached 2.5%. In 2022, there will be 4.82 million new cases of malignant tumors and 3.21 million deaths in my country, ranking first in the world. Classic clinical treatments for tumors include local therapies such as surgery and radiotherapy, as well as systemic therapies such as chemotherapy, endocrine therapy, and molecular targeted therapy. These treatments can significantly improve the prognosis of tumor patients. However, after the above-mentioned treatments, the 5-year survival rate of tumor patients in developed countries such as the United States is still less than 70%, and new tumor treatment strategies are urgently needed. Immunotherapy is a revolutionary progress in the field of tumor treatment and has opened up a new paradigm in the field of cancer treatment, which is expected to completely cure cancer. Studies have shown that regulatory T cell (Treg)-mediated immunosuppression can cause tumor cells to escape the attack of the immune system. Among them, one of the main pathways is that increased fatty acid metabolism in the tumor microenvironment leads to the accumulation of intracellular lipid droplets in Treg cells, promoting mitochondrial fatty acid β-oxidation, thereby causing immunosuppression.
[0003] CD36 is a scavenger receptor that plays an important role in lipid metabolism and is involved in angiogenesis, inflammatory response, atherosclerotic thrombosis, etc. In the immune system, CD36 mediates the uptake of fatty acids by tumor-infiltrating CD8+T cells, causing lipid peroxidation and ferroptosis, leading to reduced production of tumor toxic factors and T cell exhaustion. At the same time, studies have shown that CD36 is a specific target for Treg cells, and CD36 is only highly expressed in Treg cells in the tumor microenvironment. The most important thing is that CD36 targeting Treg cells does not cause autoimmune reactions, but significantly enhances the anti-tumor activity of immune cells. CD36 antibodies show anti-tumor activity in mouse tumor models and have a synergistic effect with PD-1 antibodies. Therefore, specific blocking of CD36 and hindering the recognition and transmembrane transport of fatty acids are effective ways to achieve precise regulation of Treg cell fatty acid metabolism and enhance immune cell function.
[0004] Through preliminary literature research, we found that there are few reports on peptide drugs targeting CD36 as immunotherapy. Therefore, it is still an important issue in this field to continue to provide preparations with considerable CD36 affinity and to provide the application of such molecules in the diagnosis and treatment of diseases. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a self-assembling polypeptide having a targeting effect on CD36 protein.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] A self-assembling polypeptide with a targeting effect on CD36 protein, the self-assembling polypeptide consists of an R3 specific targeting unit, an R2 self-assembling unit, and an R1 hydrophobic unit connected in sequence via amide bonds; the R1 hydrophobic unit is a C8-C20 alkyl carboxylic acid, the R2 self-assembling unit is a multiple hydrogen bond polypeptide sequence, and the R3 specific targeting unit is a polypeptide with specific targeting to CD36 protein that has been screened through a polypeptide library.
[0008] Furthermore, the starting acid of the R1 hydrophobic unit is a C8-C20 alkyl carboxylic acid; the starting acid of the R3 specific targeting unit is an amino acid fixed with Wang resin; the common starting acid of the R2 self-assembly unit and the R3 specific targeting unit is an amino acid protected by Fmoc or Boc; the amino acid sequence of the self-assembly polypeptide is: GViRTIR, GGGViRTIR, GVIRTIR, GGGVIRTIR.
[0009] Furthermore, the self-assembling polypeptide molecule has one or more amino acids deleted, inserted or replaced and has a polypeptide derivative with the same biological function as the self-assembling polypeptide molecule.
[0010] Furthermore, the polypeptide has a targeting effect on CD36 and can specifically bind to CD36.
[0011] Furthermore, a method for preparing a self-assembling polypeptide having a targeting effect on CD36 protein is characterized in that: amino acids fixed by Wang resin, amino acids protected by Fmoc or Boc, and C8-C20 alkyl carboxylic acids are used as raw materials to prepare the self-assembling polypeptide by a solid phase synthesis method;
[0012] The synthesis order of the self-assembling polypeptide is that R3, R2, and R1 are connected in sequence via amide bonds, and each amino acid is deprotected and then condensed in sequence, which is repeated multiple times until all amino acids and alkyl carboxylic acids are connected.
[0013] Furthermore, a self-assembling polypeptide having a targeting effect on CD36 protein is used in the preparation of an anti-tumor drug.
[0014] Furthermore, the anti-tumor drug comprises the polypeptide and a pharmaceutically active ingredient, or comprises the polypeptide and a drug delivery carrier.
[0015] Furthermore, the anti-tumor drug is in any therapeutically acceptable dosage form.
[0016] Furthermore, the preferred dosage form of the anti-tumor drug is an injectable preparation.
[0017] Furthermore, the anti-tumor drug is any drug at a therapeutically acceptable dose.
[0018] The beneficial effects of the present invention are:
[0019] 1. The self-assembling polypeptide provided by the present invention has a targeting effect on CD36, can specifically bind to CD36 and achieve a functional blocking effect. In the present invention, after the polypeptide recognizes the CD36 protein, it promotes the spontaneous formation of complex, orderly, regular, and high-level structure nanofibers with blocking function between polypeptide molecules through non-covalent bonds or intermolecular forces (hydrogen bonds, hydrophobic bonds, π-π stacking, ionic bonds, van der Waals forces and electrostatic attraction, etc.), thereby blocking the CD36 receptor function.
[0020] 1. The self-assembling polypeptide provided by the present invention has many advantages such as small relative molecular weight, high specificity, low cost, etc., and shows unique advantages in the targeted diagnosis and treatment of tumors. It has extremely important and broad application prospects, and also has good economic and social effects.
[0021] Other advantages, objectives and features of the present invention will be described in the following description and will be apparent to those skilled in the art to some extent, or those skilled in the art may be taught from the practice of the present invention. The objectives and other advantages of the present invention may be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to make the purpose, technical solution and beneficial effects of the invention clearer, the present invention provides the following drawings for illustration:
[0023] Figure 1 This is a mass spectrometry characterization diagram of the self-assembling polypeptide in Invention Example 1;
[0024] Figure 2 This is a characteristic morphology diagram of the nano solution in Invention Example 2 under a transmission electron microscope;
[0025] Figure 3 This is a graph showing the detection of cellular fatty acids in the nano solution in Invention Example 3;
[0026] Figure 4 This is a diagram showing the changes in Treg cells in mouse tumors in Example 4 of the invention.
[0027] Figure 5 This is a graph showing the inhibition results of SRP in inhibiting tumor growth in Example 4 of the invention. DETAILED DESCRIPTION
[0028] The following description is only a preferred embodiment of the present invention and does not limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
[0029] The object of the present invention is to provide a self-assembling polypeptide with targeting effect on CD36 protein, which meets the demand of continuously providing substances with CD36 affinity, specifically binds to CD36 protein, and is suitable for therapeutic and diagnostic applications.
[0030] Another object of the present invention is to provide a CD36 protein binding polypeptide, which can be used as a part of a fusion polypeptide.
[0031] To achieve the content of the invention, the present invention adopts the following inventive technologies:
[0032] The present invention is a self-assembling polypeptide with a targeting effect on CD36 protein, the polypeptide comprises an R1 hydrophobic unit, an R2 self-assembling unit and an R3 specific targeting unit, and each unit is connected via an amide bond. The structural example is shown below:
[0033] R1-R2-R3
[0034] The R3 specific targeting unit can bind to the CD36 protein and interact with the ligand receptor, causing the R2 unit with multiple hydrogen bonds to deform, thereby achieving the transformation from nanoparticles to nanofibers, and then covering the entire CD36 molecule, affecting the functional operation of CD36.
[0035] The present invention also provides a method for preparing a self-assembling polypeptide having a targeting effect on CD36 protein, and the specific method is as follows:
[0036] The product is prepared by a solid phase synthesis method using Wang resin-fixed amino acids, Fmoc- or Boc-protected amino acids, and C8-C20 alkyl carboxylic acids as raw materials.
[0037] The synthesis sequence is from R3 to R2 and then to R1. Each amino acid is deprotected and then condensed in sequence, and this process is repeated until all amino acids and alkyl carboxylic acids are connected.
[0038] Example 1
[0039] A self-assembling polypeptide (hereinafter referred to as SRP) having a targeting effect on CD36 protein, the chemical structure of SRP is:
[0040] CH3(CH2)CO-FFKLV-GViRTIR
[0041] SRP was obtained by solid phase synthesis and characterized by mass spectrometry. Figure 1 As shown, the main peak of the mass spectrum is basically consistent with the molecular weight of the SRP polypeptide, so it can be considered that the target polypeptide is successfully obtained.
[0042] Example 2
[0043] To explore whether self-assembling polypeptides can recognize CD36 protein and undergo deformation.
[0044] The SRP in Example 1 was dissolved in DMSO, and 10 μL of the solution was taken out and dissolved in 990 μL of pure water to prepare a nano solution of SRP.
[0045] The nano-solution was co-incubated with CD36 protein at a concentration of 1×10-7M, and the morphological characteristics at 0h, 1h, 4h, and 6h were observed under a transmission electron microscope. Figure 2 As shown, SRP can well recognize CD36 and undergo deformation.
[0046] Example 3
[0047] To explore whether self-assembling peptides can affect the lipid uptake function of cells with high CD36 expression.
[0048] The SRP in Example 1 was made into a nano solution with a concentration of 50 μM, incubated with the CD36-high-expressing cells Raw264.7 for 12 hours, and then incubated with Bodipy-C12 for 30 minutes. The cellular fatty acid uptake was detected by flow cytometry. The results are as follows: Figure 3 As shown, SRP can effectively inhibit the lipid uptake function of cells with high CD36 expression.
[0049] Example 4
[0050] To explore whether self-assembling peptides can affect Treg cells with high expression of CD36 in the tumor immune microenvironment and bring about tumor treatment effects.
[0051] B16-F10 cells were used to establish a tumor model in C57BL / 6J mice. The tumor growth was observed and a 7.5 mg / kg SRP peptide solution was injected on the 8th day after tumor cell injection. After five treatments, flow cytometry was used to examine the changes in Treg cells in tumor tissues. The results are as follows: Figure 4 As shown in Figure 2, SRP peptide can reduce the number of Treg cells in tumor tissue. The tumor growth was observed and the results were as follows: Figure 5 As shown, SRP polypeptide can also inhibit tumor growth to a certain extent.
[0052] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.
Claims
1. A self-assembling polypeptide having a targeting effect on CD36 protein, characterized in that: The self-assembling polypeptide consists of an R3 specific targeting unit, an R2 self-assembling unit, and an R1 hydrophobic unit which are sequentially connected via amide bonds; the R1 hydrophobic unit is a C8-C20 alkyl carboxylic acid, the R2 self-assembling unit is a multiple hydrogen bond polypeptide sequence, and the R3 specific targeting unit is a polypeptide with specific targeting to CD36 protein which has been screened through a polypeptide library.
2. A self-assembling polypeptide having a targeting effect on CD36 protein according to claim 1, characterized in that: The starting acid of the R1 hydrophobic unit is a C8-C20 alkyl carboxylic acid; the starting acid of the R3 specific targeting unit is an amino acid fixed with Wang resin; the common starting acid of the R2 self-assembly unit and the R3 specific targeting unit is an amino acid protected by Fmoc or Boc; the amino acid sequence of the self-assembly polypeptide is: GViRTIR, GGGViRTIR, GVIRTIR, GGGVIRTIR.
3. A self-assembling polypeptide having a targeting effect on CD36 protein according to claim 2, characterized in that: The self-assembling polypeptide molecule is a polypeptide derivative in which one or more amino acids are deleted, inserted or replaced and has the same biological function as the self-assembling polypeptide molecule.
4. A self-assembling polypeptide having a targeting effect on CD36 protein according to claim 3, characterized in that: The polypeptide has a targeting effect on CD36 and can specifically bind to CD36.
5. A self-assembling polypeptide having a targeting effect on CD36 protein according to any one of claims 1 to 4, further comprising a method for preparing a self-assembling polypeptide having a targeting effect on CD36 protein, characterized in that: The self-assembling polypeptide is prepared by solid phase synthesis using amino acids fixed by Wang resin, amino acids protected by Fmoc or Boc, and C8-C20 alkyl carboxylic acids as raw materials; The synthesis order of the self-assembling polypeptide is that R3, R2, and R1 are connected in sequence via amide bonds, and each amino acid is deprotected and then condensed in sequence, which is repeated multiple times until all amino acids and alkyl carboxylic acids are connected.
6. Use of a self-assembling polypeptide having a targeting effect on CD36 protein according to any one of claims 1 to 4 in the preparation of an anti-tumor drug.
7. Use of a self-assembling polypeptide having a targeting effect on CD36 protein according to claim 6 in the preparation of an anti-tumor drug, characterized in that: The anti-tumor drug comprises the polypeptide and a pharmaceutically active ingredient, or comprises the polypeptide and a drug delivery carrier.
8. The use of a self-assembling polypeptide having a targeting effect on CD36 protein according to claim 7 in the preparation of an anti-tumor drug, characterized in that: The anti-tumor drug is in any therapeutically acceptable dosage form.
9. The use of a self-assembling polypeptide having a targeting effect on CD36 protein according to claim 8 in the preparation of an anti-tumor drug, characterized in that: The dosage form of anti-tumor drugs is injection preparation.
10. Use of a self-assembling polypeptide having a targeting effect on CD36 protein according to claim 9 in the preparation of an anti-tumor drug, characterized in that: The anti-tumor drug is any drug in a therapeutically acceptable dose.
Citation Information
Patent Citations
Polypeptide, hydrogel and application
CN116253805A
Enhancement of the immune response using CD36-binding domain
WO2003050268A2
Cited By
Targeted vcam1 endothelial cell self-assembled polypeptide nano-material and application thereof in xenotransplantation
CN120983643A
